J Oyee

Medicine · Health Sciences

19h-index1.3kcitations79works2.42yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(14), HIV/AIDS drug development and treatment(11), HIV Research and Treatment(8), Lung Cancer Diagnosis and Treatment(7), HIV/AIDS Research and Interventions(6)

Publications79 total

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study
EClinicalMedicine·2025· 1 citedOpen Access
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study
EClinicalMedicine·2025Open Access
Pharmaceutical Practice Considerations Regarding Adoption of the Race-Free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 Equations
American Journal of Kidney Diseases·2025· 1 cited
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
AIDS and Behavior·2024· 2 citedOpen Access
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled <scp>TANGO</scp> and <scp>SALSA</scp> studies
HIV Medicine·2024· 4 citedOpen Access
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study
Open Forum Infectious Diseases·2024· 1 citedOpen Access
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies
Viruses·2024· 3 citedOpen Access
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
JAIDS Journal of Acquired Immune Deficiency Syndromes·2024· 7 citedOpen Access
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study
Open Forum Infectious Diseases·2023· 6 citedOpen Access
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Clinical Infectious Diseases·2022· 152 citedOpen Access
TROCA PARA UM REGIME COM 2 MEDICAMENTOS DOLUTEGRAVIR / LAMIVUDINA (DTG / 3TC) EM DOSE FIXA COMBINADA É NÃO INFERIOR A CONTINUAR COM UM REGIME DE 3 MEDICAMENTOS POR 48 SEMANAS EM UM ENSAIO CLÍNICO RANDOMIZADO (SALSA)
The Brazilian Journal of Infectious Diseases·2022Open Access
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of <scp>HLA</scp>‐B*5701 Screening as a Risk‐Mitigation Measure
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy·2018· 21 citedOpen Access
Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials
Open Forum Infectious Diseases·2018· 40 citedOpen Access
Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials
Open Forum Infectious Diseases·2017· 1 citedOpen Access
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation
Health Technology Assessment·2015· 3 citedOpen Access
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
Thorax·2015· 117 citedOpen Access
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation
SHILAP Revista de lepidopterología·2014Open Access
Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal
PharmacoEconomics·2014· 17 cited
Are Health Technology Assessments of Pharmacogenetic Tests Feasible? A Case Study of <i>CYP2D6</i> Testing in the Treatment of Breast Cancer with Tamoxifen
Personalized Medicine·2013· 4 cited
Assessment of factors relevant to the NHS and other parties
2013
page 1 of 4Next →

Frequent Co-authors

Angela Boland(29), Y Dündar(28), A Bagust(22), C Martin Saborido(16), J Greenhalgh(16), Rumona Dickson(13), Gerlinde Pilkington(11), Catrin Tudur Smith(9), R Dickson(9), M Blundell(9), Brian Wynne(7), Tamara Brown(6), Nigel Fleeman(6), R Dickson(6), Bryn Jones(6), Jo Hockenhull(5), M Blundell(4), Mei‐Shu Lai(4), Rimgaile Urbaityte(4), Mounir Ait‐Khaled(4)